Ternary Therapeutics

Ternary Therapeutics, a London-based biotech startup founded in 2024, has successfully closed a £3.6 million seed funding round. This investment will fuel the development of its innovative AI platform designed to systematically create 'molecular glues,' a novel class of medicines capable of targeting previously 'undruggable' proteins.

Summary of transaction details:

• Value: £3.6 million seed investment
• Sector: Biotechnology, AI in Drug Discovery, Health Tech
• Advisor: None mentioned
• Key Entities:
  Target: Ternary Therapeutics
  Lead Investor: daphni
  Other Investors: Pace Ventures, i&i Biotech Fund, UK Innovation & Science Seed Fund (managed by Future Planet Capital)
• Location: London, UK (Target Company)

Note: The strategic rationale behind this funding is to capitalize on the transformative potential of AI and machine learning to overcome the historical challenges in discovering molecular glues. By enabling intentional design rather than chance discovery, Ternary Therapeutics aims to accelerate the development of highly effective drugs for complex diseases, positioning itself at the forefront of precision medicine.